Nektar Q2 FY26 net loss narrows to $40.62 million; revenue falls 9.35% to $10.1 million
NKTR•Q2 results and cash position
- Nektar Therapeutics posted a Q2 net loss of $40.62 million, narrowing from $41.59 million a year earlier.
- Loss per share narrowed to $1.23 from $2.95, while revenue slipped to $10.13 million from $11.18 million.
- Operating costs and expenses rose to $52.47 million from $47.41 million, driven by higher R&D of $39.13 million versus $29.89 million.
- Cash and marketable securities climbed to $1.02 billion at June 30 from $245.8 million at Dec. 31, following a $373.8 million stock offering.
- Phase 3 ZENITH AD trials in atopic dermatitis began in July; a registrational Phase 3 alopecia areata study is planned for early 2027.
